Insider trade

Dexcom (DXCM): Officer sold ~$110K

Michael Jon Brown, Officer at Dexcom, sold ~$110K of Dexcom shares.

~$110K
Approx. value · 1,700 sh @ $64.85
113K
Holds after · shares reported
Traded
Mar 16, 2026
Filed
Mar 18, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Jan 26, 2026CongressDisclosed purchase of DXCM — reported range $1,001 - $15,000
  2. Feb 3, 2026FDAFDA device clearance: Dexcom G7 Continuous Glucose Monitoring (CGM) System; Dexcom G7 15 Day Continuous Glucose Monitoring (CGM) System
  3. Feb 12, 2026Company filing · Form 8-K · ResultsReported its results
  4. Feb 12, 2026InsiderDirector sold ~$69K of DXCM shares in the open market
  5. Feb 26, 2026Company filing · Form 8-K · Executive change, Reg FDChanged a top executive or board member, and shared information with investors“On February 26, 2026, the Board of Directors (the “Board”) of DexCom, Inc. (“Dexcom” or the “Company”), pursuant to the Amended and Restated Bylaws of the Company, increased the size of the Board to twelve directors and appointed Albert F. (“Rick”) Osterloh, IV as a director effective immediately.”
  6. Feb 27, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“As previously reported on the Current Report on Form 8-K filed on July 30, 2025, Kevin R. Sayer notified the Board of Directors (the “Board”) of DexCom, Inc. (“Dexcom” or the “Company”) of his intent to retire from his role as Chief Executive Officer effective January 1, 2026.”
  7. Mar 16, 2026 · this disclosureInsiderOfficer sold ~$110K of DXCM shares in the open market

What came next

  1. Mar 26, 20265% stakeThe Vanguard Group reported a passive stake (13G)
  2. Apr 14, 2026FDARecall: Brand Name: Dexcom G7 Continuous Glucose Monitoring System Product Name: Dexcom G7 CGM watchOS App Model/Catalog Number: SW13355 Software Version: Versions 2.9…
  3. Apr 14, 2026FDARecall: Brand Name: Dexcom G7 Continuous Glucose Monitoring System Product Name: Dexcom G7 CGM iOS App Model/Catalog Number: SW12300 Software Version: Versions 2.9.0 t…
  4. Apr 14, 2026FDARecall: Brand Name: Dexcom ONE+ Continuous Glucose Monitoring System Product Name: Dexcom ONE+ iOS CGM App Model/Catalog Number: SW14244 Software Version: versions 1.5…
  5. Apr 15, 2026InsiderOfficer sold ~$107K of DXCM shares in the open market
  6. Apr 29, 20265% stakeVanguard Portfolio Management reported a passive stake (13G) of 5.0%
  7. Apr 29, 20265% stakeVanguard Capital Management reported a passive stake (13G) of 7.5%
  8. Apr 29, 2026CongressDisclosed partial sale of DXCM — reported range $100,001 - $250,000
  9. Apr 30, 2026Company filing · Form 8-K · ResultsReported its results
  10. May 7, 2026CongressDisclosed sale of DXCM — reported range $100,001 - $250,000
  11. May 12, 2026InsiderDirector sold ~$61K of DXCM shares in the open market
  12. May 15, 2026InsiderOfficer sold ~$102K of DXCM shares in the open market
  13. May 21, 2026FDAFDA device clearance: Stelo Glucose Biosensor System
  14. May 21, 2026InsiderChair sold ~$1.93M of DXCM shares in the open market
  15. May 27, 2026FDARecall: Brand Name: Dexcom G7 Continuous Glucose Monitoring System Product Name: Dexcom G7 US Retail Sensor/Transmitter 1-pack Model/Catalog Number: STP-AT-012 Softwar…
  16. Jun 3, 2026InsiderOfficer sold ~$359K of DXCM shares in the open market
  17. Jun 4, 2026InsiderOfficer sold ~$364K of DXCM shares in the open market
  18. Jun 8, 2026FDAFDA device clearance: Dexcom G7 Continuous Glucose Monitoring System;Dexcom G7 15 Day Continuous Glucose Monitoring System
  19. Jun 12, 2026FDAFDA device clearance: Stelo Glucose Biosensor System
  20. Jun 15, 2026Insider · 2 peopleInsiders: 3 sales (~$425K)
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Dexcom

For Dexcom, OQRO holds 20 insider filings (SEC Form 4 or Form 144) and 1 fund holdings report (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its DXCM page.

Other recent filings by Michael Jon Brown, EVP, Chief Legal Officer

The full history of Michael Jon Brown, EVP, Chief Legal Officer is on the profile page.

How this filing works

Explore the data

Common questions

Which Dexcom (DXCM) insider traded, and how much?

Michael Jon Brown, Officer at Dexcom, sold ~$110K of Dexcom shares. 1,700 shares at $64.85.

When did it happen, and when was it made public?

Traded: Mar 16, 2026. Filed: Mar 18, 2026. That is 2 days between the two dates.

Is the dollar amount exact?

It is the number of shares multiplied by the price the insider reported on the form. A grant, a gift or an option exercise has no market price, so those show shares only.

Where does this information come from?

From the SEC Form 4, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.

What else has been disclosed about Dexcom recently?

For Dexcom, OQRO holds 20 insider filings (SEC Form 4 or Form 144) and 1 fund holdings report (13F) dated in the last 90 days. They are listed on the DXCM page.

Does this mean DXCM stock is a buy or a sell?

No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.

Is OQRO free?

Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.

Other disclosures at Dexcom

Everything OQRO holds on this company is on its DXCM page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data